SLC19A1 and neuroblastoma: These findings may support the previous studies [6, 10] that SLC19A1 is a direct transcription target of MYCN in neuroblastomas, and pralatrexate treatment affects SLC19A1 expression in MYCN amplified cells, but not SLC25A32 expression.